sb 216763 has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, MJ; Carter, PS; Coghlan, MP; Corcoran, SL; Cross, DA; Culbert, AA; Haigh, D; Holder, JC; Mills, D; Murphy, GJ; Murray, KJ; Pearce, NJ; Rausch, OL; Reith, AD; Roxbee Cox, L; Smith, DG; Ward, RW; Yates, JW | 1 |
| Flajolet, M; Greengard, P; Meijer, L | 1 |
1 review(s) available for sb 216763 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Pharmacological inhibitors of glycogen synthase kinase 3.
Topics: Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Neoplasms; Nervous System Diseases; Parasitic Diseases; Signal Transduction; Stem Cells; Structure-Activity Relationship | 2004 |
1 other study(ies) available for sb 216763 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.
Topics: Adenosine Triphosphate; Aminophenols; beta Catenin; Binding, Competitive; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Cytoskeletal Proteins; Diabetes Mellitus, Type 2; Enzyme Activation; Gene Expression Regulation; Genes, Reporter; Glycogen; Glycogen Synthase; Glycogen Synthase Kinase 3; Glycogen Synthase Kinases; Humans; Indoles; Kinetics; Liver; Maleimides; Molecular Structure; Neurodegenerative Diseases; Protein Kinases; Recombinant Proteins; Signal Transduction; Trans-Activators; Transcription, Genetic | 2000 |